Värde Partners Exceeds Target Raising Nearly $2.5 Billion in 13th Flagship Fund
18.12.2019 20:32:00 EET | Business Wire | Press release
Värde Partners, a leading global alternative investment firm, today announced it has raised its 13th flagship vehicle, Värde Fund XIII (“the Fund”), with $2.47 billion in commitments.
The Fund exceeded its $2 billion target and will have the flexibility to invest in a range of credit and credit-related assets globally across liquid traded credit, special situations, real estate and financial services.
“Over the past 26 years we have built a global platform with the agility to seek attractive risk-adjusted value in opportunistic credit and asset markets,” said George Hicks, Co-Founder and Chief Executive Officer. “In this fund, we utilize our deep experience through many market cycles with the flexibility to invest in both private and liquid markets, across capital structures and regions.”
Värde expects the opportunity set to be driven by systemic distress factors, including where financial systems retain persistent high levels of non-performing loans, and cyclical opportunities associated with industry or economic downturns.
“Against a backdrop of intense economic uncertainty, there are several significant pockets of distress around the world today, and we expect that opportunity to grow over the investment period of the Fund,” said Ilfryn Carstairs, Global Co-Chief Investment Officer. “We have strategically built our right to play in markets where we can target the gaps left behind by traditional capital providers as they continue to retrench.”
“The strong support for this fundraise came from both new and long-time investors,” added Jon Fox, Partner and Global Head of Business Development and Investor Relations. “We appreciate the confidence that this diverse investor base has in the power of the Värde platform.”
In addition to its flagship funds, Värde has previously raised dedicated capital for targeted investment strategies in Asia, Europe, mortgages, private debt, real estate, and specialty finance.
Värde Partners is a leading global alternative investment firm with roots in credit and distressed. Founded in 1993, the firm has invested more than $68 billion since inception and manages over $14 billion on behalf of a global investor base. The firm’s investments span corporate and traded credit, real estate and mortgages, private equity and direct lending. Värde employs more than 300 professionals across 13 offices worldwide. For more information, please visit www.varde.com.
# # #
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191218005641/en/
Contact information
Värde Partners
Andrea Raphael, Global Head of Communications & Public Affairs
communications@varde.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Fastly Joins DIMPACT to Collaborate on Digital Sustainability8.7.2026 15:00:00 EEST | Press release
Fastly, Inc. (NASDAQ: FSLY), a leading global edge cloud platform, today announced it has become a participant of DIMPACT, the coalition of leading organizations working to align industry changemakers and policymakers around meaningful, science-based solutions that reduce the environmental impacts of serving digital media products. As the first edge cloud platform provider to join the coalition, Fastly brings critical, real-world edge network data and infrastructure expertise and a transparent approach to emissions calculation and reporting to help major media, streaming, and publishing companies understand and optimize their digital carbon footprints. “We’re thrilled to welcome Fastly to the DIMPACT initiative. Their participation strengthens DIMPACT's ability to advance a more accurate, data-driven approach to measuring and reducing digital emissions,” said Jason Bell, Director at SLR Consulting and Executive Sponsor of DIMPACT. “Accurately calculating digital emissions requires a de
PubNub Introduces Blocks.ai: The Control Plane and Network Layer For AI Agents8.7.2026 15:00:00 EEST | Press release
PubNub introduces Blocks.ai today, a global network to connect and control agents across all agent frameworks, providers, and APIs. Blocks.ai lets developers reach their existing AI agents regardless of where they are hosted. Blocks Network supports all AI agent use cases without opening inbound ports, setting up tunnels, changing DNS, or modifying firewall rules. For more than a decade, PubNub has been the infrastructure and platform for real-time connectivity supporting billions of devices, now, PubNub delivers Blocks Network connecting the Internet of Agents. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260708521206/en/ AI agents have become increasingly critical to businesses who want control over their models, code, and data. But once those agents are running locally or behind a firewall, making them reachable from custom frontends can require brittle infrastructure work. This is a key reason why McKinsey estimates th
STEMCELL Technologies and CCRM Partner to Expand Access to Matched GMP and RUO iPSC Lines for Cell Therapy Development8.7.2026 15:00:00 EEST | Press release
STEMCELL Technologies and the Centre for Commercialization of Regenerative Medicine (CCRM) today announced a partnership to expand access to high-quality human induced pluripotent stem cell (iPSC) starting materials, giving cell therapy developers worldwide a faster, lower-risk path from research to the clinic. Under the agreement, STEMCELL will manufacture and distribute research-use-only (RUO) iPSC lines derived directly from LineaBio's Good Manufacturing Practices (GMP) iPSC lines, and will offer the matched GMP lines to developers worldwide. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260708212795/en/ Partnership pairs GMP-manufactured iPSC lines with matched RUO equivalents, giving developers well-characterized, donor-eligible starting materials from early research through clinical development. Supporting comparability data for the RUO and GMP lines to be presented at the 2026 ISSCR Annual Meeting in Montréal, Canada
LUMI AI Factory Selects IQM to Deploy Advanced Quantum Computer, Accelerating Hybrid HPC and AI Development8.7.2026 15:00:00 EEST | Press release
The LUMI AI Factory, led by CSC – IT Center for Science, has selected IQM Quantum Computers (Nasdaq: IQMX) to deliver IQM Halocene H4, an advanced quantum computer aimed at accelerating hybrid high-performance computing, artificial intelligence, and quantum computing capabilities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260708006791/en/ LUMI AI Factory selects IQM to deploy advanced quantum computer, accelerating hybrid HPC and AI development IQM Halocene H4 is the first and most advanced on-premises superconducting quantum computer of its kind, combining quantum error correction with NISQ qubits. The system will be delivered in 2027, followed by a series of upgrades delivered in multiple phases with an increasing number of logical qubits. The IQM Halocene H4 and the upgraded systems will enable LUMI consortium users, for the first time, to develop and implement Quantum Error Correction (QEC) concepts on a world-leadi
Merck Announces FDA Breakthrough Therapy Designation for Enpatoran in Lupus Patients With Active Skin Manifestations8.7.2026 15:00:00 EEST | Press release
Merck, a leading science and technology company, today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to enpatoran for the treatment of lupus with active cutaneous manifestations. Enpatoran is an oral selective toll-like receptor (TLR) 7/8 inhibitor, designed to modulate pathways central to lupus-related inflammation. “For the 85% of lupus patients whose disease includes skin manifestations, often associated with substantial physical and psychosocial burden, the lack of targeted treatment makes the disease hard to control,” said David Weinreich, MD, MBA, Global Head of R&D and Chief Medical Officer for the Healthcare business of Merck. “This Breakthrough Therapy designation demonstrates that enpatoran has the potential to redefine how we approach lupus, by addressing the visible burden of rash, while potentially driving benefit beyond the skin. We look forward to working with the FDA to potentially bring this much-needed option to
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom